傲慢与偏见
AMD、Google、微软、英伟达宣布Caliptra开源信任根_我的网站
一 |
China has granted marketing approval of its first drug for the prevention of acute mountain sickness, filling the long-standing gap in the domestic market where no such medications had been available, Science and Technology Daily reported on Tuesday.
The National Medical Products Administration (NMPA) has approved the marketing of acetazolamide sustained-release capsules, the report said. As the first specialized drug in China indicated for preventing of acute mountain sickness, its approval marks the end of the country's lack of dedicated preventive treatment for altitude illness.
By inhibiting the activity of carbonic anhydrase, acetazolamide promotes the renal excretion of bicarbonate, corrects respiratory alkalosis caused by hypoxia at high altitudes, thereby regulating acid-base balance, optimizing respiratory status, elevating blood oxygen levels, and reducing the risk of onset at the source.
In contrast to health products that only provide auxiliary regulatory effects, this medication has been validated through stringent clinical trials and stands as a specialized drug approved by the NMPA with a clear indication for prevention, said the report.
Led by principal investigator is Luobu Gesang, a deputy dean of the People's Hospital of Xizang Autonomous Region, the clinical trial was designed by his team and has yielded critical evidence to inform prevention strategies for altitude sickness that are specifically adapted to Chinese and Asian populations.
"Previously, although acetazolamide had already been used internationally for the prevention of acute mountain sickness, China had long lacked an NMPA-approved acetazolamide formulation supported by rigorous clinical trials. Furthermore, the existing international formulations were short-acting tablets requiring multiple daily doses, and no drugs with the relevant indication were available on the domestic market for an extended period," said Luobu Gesang.
The sustained-release capsule approved this time not only fills this critical gap but also optimizes the dosage form, providing more reliable and convenient medication protection for the physical health and life safety of people entering high-altitude areas, he added.
Clinical trials showed that, compared with the placebo group, the incidence of acute mountain sickness in the medication group was significantly reduced, with the incidence of moderate-to-severe acute mountain sickness decreasing by 14.6 percent, according to the report.
Related research has been published in the international flagship journal of high-altitude medicine, High Altitude Medicine & Biology.
Global Times
。
二 | 更重要的是，Caliptra 完全开源，辅以配套的 RTL / 固件。它能够为 SoC 安全配置提供可验证的加密保证，并确保启动代码是可信的。Caliptra 旨在完全集成到 SoC / ASIC 中，以提供与当今单独的信任根解决方案相媲美的集成安全性，同时它围绕现代边缘 / 机密计算场景的需求而设计。有趣的是，Caliptra 的参考实现，使用了 RISC-V 内核。
三 | 奇怪的是，虽然红（AMD）蓝（NVIDIA）都已官宣支持 Caliptra，但蓝厂（Intel）却在今日的公告中意外缺席。至于具有 Caliptra 硅信任根的目标，新规范中是这么描述的：在本质上，Caliptra Silicon RoT 的范围是刻意做到极简的，以推动规范定义的敏捷性、最大限度地提高适用性，并且推动行业对齐、一致性和更快地采用基础设备安全原语。一个定义明确的规范，可在最大限度上提升架构的可组合性，跨 CSP、产品和供应商的可重用性，以及开源的可行性。虽然增强功能、高级用例和应用程序超出了本规范的范围，但各方仍可通过硅 RoT 和社区参与的途径，加入到这一开发路线图中。
四 | Caliptra 定义了硅内部 RoT 基线的设计标准，满足测量信任根（RTM）角色。并且 Caliptra 的开源实现，推动了 RTM 和锚定硬件证明的测量机制的透明度。需要注意的是，Caliptra Silicon RoT 必须启动 SoC、测量其加载的可变代码，以及控制 SoC 中非易失性配置位的突变。最后，Caliptra Silicon RoT 使用基于独特的“每资产加密熵”的签名证明来报告这些测量结果，因而能够作为 SoC 身份的信任根。感兴趣的朋友，可移步至 OpenCompute.org 官网了解完全开放的 Caliptra 规范。至于更多技术细节，还请留意本周的 OCP（开放计算项目）活动。
Current article:http://s0vi0g.minshixuanhabing.bond/news/20260826_747.xls
Published on:18:35:10
